Company profile: Corbus Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutics targeting inflammatory and fibrotic diseases, with programs in oncology and obesity. Pipeline includes CRB-701, a next-generation Nectin-4-targeting ADC in trials for advanced solid tumors; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity with IND planned.
Products and services
- CRB-601: A clinical-stage, anti-integrin monoclonal antibody engineered to block activation of TGFβ expressed on cancer cells, with ongoing clinical development
- CRB-701: An investigational, next-generation antibody-drug conjugate targeting Nectin-4 to treat advanced solid tumors with high Nectin-4 expression, currently assessed in clinical trials
- CRB-913: A preclinical, highly peripherally restricted CB1 inverse agonist architected for obesity treatment, with pre-clinical data presented and an IND filing planned
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Corbus Pharmaceuticals
Kynos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule KMO inhibitor therapeutics for inflammation, immunity, and metabolism. Offers KNS366, a Phase I KMO inhibitor designed to reduce elevated 3-HK to prevent tissue damage and immune dysregulation during inflammation, and a portfolio targeting acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kynos Therapeutics company profile →
Philogen
HQ: Italy
Website
- Description: Provider of biopharmaceuticals targeting angiogenesis and tumor-associated blood vessels for the treatment of cancer and other serious conditions, with a pipeline including Nidlegy (clinical-stage), Fibromun (in clinical development), Darleukin for selective delivery to tumor sites, Dekavil and Dodekin targeting vascular antigens, and Onco IX utilizing vascular targeting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Philogen company profile →
IMMCO Diagnostics
HQ: United States
Website
- Description: Provider of innovative medical devices, diagnostic laboratory testing expertise, and pioneering research for a comprehensive solution to autoimmune disease diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IMMCO Diagnostics company profile →
Gyre Therapeutics
HQ: United States
Website
- Description: Provider of protease therapeutics to address disorders of the coagulation system, operating as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gyre Therapeutics company profile →
Equillium
HQ: United States
Website
- Description: Provider of therapeutics for autoimmune and inflammatory disorders, including itolizumab, a clinical-stage monoclonal antibody targeting the CD6-ALCAM pathway; EQ101, a tri-specific cytokine inhibitor of IL-2/IL-9/IL-15 in Phase 2 for alopecia areata; EQ302, an oral bi-specific inhibitor of IL-15/IL-21 in pre-clinical; and a multi-cytokine platform generating composite peptides to selectively block key cytokines at shared receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Equillium company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Corbus Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Corbus Pharmaceuticals
2.2 - Growth funds investing in similar companies to Corbus Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Corbus Pharmaceuticals
4.2 - Public trading comparable groups for Corbus Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →